Stability and Purity Issues Lead to Recall of Tydemy
One of the two recalled lots of the birth control tested high for a known impurity.
Lupin Pharmaceuticals is voluntarily recalling two lots of Tydemy (drospirenone, ethinyl estradiol and levomefolate calcium), because of results of a 12-month stability test. Additionally, one lot tested low for ascorbic acid (an inactive ingredient) and high for a known impurity.
Tydemy is estrogen/progestin oral contraceptive used to prevent pregnancy. Lupin is recalling two lots because the reduction in the amount of inactive ingredient could potentially impact the effectiveness of the product and potentially result in unexpected pregnancy.
The lots were distributed nationwide in the United States to wholesalers, drug chains, mail order pharmacies and supermarkets.
The recalled lots have an NDC of 68180-904-71 for one blister packs of 28 tablets each and 68180-904-73 for three blister packs of 28 tablets each. Lot number L200183 has an expiration date of January 2024, and lot number L201560 has an expiration date of September 2024. Both lots were distributed between June 2022 and May 2023.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
